Importantly, the combined therapy group displayed a higher proportion of GZMB+ CD8+ T cells and PD‐L1+ tumour cells in TME compared to the anti‐PD1 antibody‐treated group, while the two groups showed no difference in PD1+CD8+ T cells (Figure 5H). This evidence concerns the gene CD8A and neoplasm.